Results of isoproterenol tilt table testing in monozygotic twins discordant for chronic fatigue syndrome

Citation
J. Poole et al., Results of isoproterenol tilt table testing in monozygotic twins discordant for chronic fatigue syndrome, ARCH IN MED, 160(22), 2000, pp. 3461-3468
Citations number
36
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
ARCHIVES OF INTERNAL MEDICINE
ISSN journal
00039926 → ACNP
Volume
160
Issue
22
Year of publication
2000
Pages
3461 - 3468
Database
ISI
SICI code
0003-9926(200012)160:22<3461:ROITTT>2.0.ZU;2-N
Abstract
Background: The pathogenesis of chronic fatigue syndrome (CFS) is unknown. Neurally mediated hypotension (NMH) has been suggested as a common comorbid condition or a potential underlying cause. Methods: We conducted a cotwin control study of 21 monozygotic twins who we re discordant for CFS. One twin met the 1994 Centers for Disease Control an d Prevention criteria for CFS, and the other twin was healthy and denied ch ronic fatigue. The twins were selected from a volunteer twin registry in wh ich at least 1 member reported persistent fatigue. As part of a 7-day clini cal evaluation, all 21 twin pairs were evaluated with a 3-stage tilt table test with isoproterenol hydrochloride for the assessment of NMH. The presen ce of NMH was defined as syncope or presyncope associated with a decrease o f 25 mm Hg in blood pressure and no associated increase in heart rate. Results: A positive tilt table test result was observed in 4 twins with CFS (19%) and in 4 healthy twins (19%). This difference was not statistically significant (matched-pair odds ratio, 1.0; 95% confidence interval, 0.2-5.4 , P>.90). Compared with the healthy twins, the twins with CFS reported more severe symptoms of CFS and NMH both in the week before and during the tilt table test. Conclusions: These results do not support a major role for NMH in CFS. They highlight the importance of selecting well-matched control subjects, as we ll as the unique value of the monozygotic cotwin control design in the stud y of this illness.